文献速递肝病

左心室质量异常作为儿童肝硬化预后标志物的研究

Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis.
PubMed 文献 · J Hepatol · 2026-10-12

本研究对比226例肝硬化与非肝硬化儿童,发现肝硬化患儿左心室质量显著增高,约25%存在左心室肥厚(OR 6.9,95%CI 3-16,P<0.0001)。左心室质量指数(LVMI)≥88、≥91、≥95 g/m2.7分别独立预测等待期失代偿、肝移植后复合严重不良事件和死亡,LVMI联合PELD-Cr/MELD可改善风险分层。

要点

  • 儿童肝硬化患者约25%存在左心室肥厚,LVMI显著高于非肝硬化对照。
  • LVMI≥88、≥91、≥95 g/m2.7分别独立预测等待期失代偿、移植后严重不良事件和死亡。
  • LVMI联合PELD-Cr/MELD在预测等待期失代偿和移植后严重不良事件上优于单独PELD-Cr/MELD。

核心结论

  • LVMI是儿童肝硬化发病率和死亡率的强预测因子,可作为预后标志物。
  • 将LVMI纳入PELD-Cr/MELD可能增强风险分层和器官分配。

研究设计与样本

  • 回顾性比较2011-2021年列于肝移植的226例肝硬化患儿与160例非肝硬化对照儿童。
  • 采用二维超声心动图、形态计量学、组织病理学和血管活性-正性肌力评分(VIS)进行评估。
  • 使用ROC分析评估LVMI预测等待期失代偿、肝移植后复合严重不良事件和死亡的判别性能,并与PELD-Cr/MELD评分比较。

主要发现

  • 肝硬化患儿二维超声和尸检标本中左心室质量显著高于非肝硬化对照,约25%存在左心室肥厚(OR 6.9,95%CI 3-16,P<0.0001)。
  • 肝硬化队列中LVMI与肝移植应激下的血管活性药物需求相关(P<0.001),且在等待期失代偿、复合严重不良事件和死亡患者中显著更高。
  • 调整PELD-Cr/MELD、胆红素和INR后,LVMI≥88 g/m2.7、≥91 g/m2.7和≥95 g/m2.7分别独立与等待期失代偿、复合严重不良事件和死亡相关(P<0.01)。
  • LVMI联合PELD-Cr/MELD在判别等待期失代偿和复合严重不良事件上显著优于PELD-Cr/MELD;LVMI单独在复合严重不良事件上显著优于PELD-Cr/MELD,在等待期失代偿上相当;三种模型在判别死亡上性能相当。

关键数值与推荐

  • LVMI≥88 g/m2.7独立关联等待期失代偿(调整PELD-Cr/MELD、胆红素和INR后P<0.01)。
  • LVMI≥91 g/m2.7独立关联肝移植后复合严重不良事件(调整后P<0.01)。
  • LVMI≥95 g/m2.7独立关联死亡(调整后P<0.01)。

临床怎么用

  • 对儿童肝硬化患者可考虑使用超声心动图测量LVMI以辅助风险分层。
  • LVMI联合PELD-Cr/MELD可能改善等待期失代偿和移植后严重不良事件的预测。
  • LVMI升高提示需关注围移植期血流动力学管理和不良结局风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Cirrhotic cardiomyopathy (CCM), a clinically consequential comorbidity of cirrhosis, remains undefined and underappreciated in children. This study aimed to characterize myocardial structural, functional, morphometric, and histopathologic features in pediatric cirrhosis and objectively derive a reliable echocardiographic (2DE) metric to predict perioperative adverse events, including mortality. METHODS: 2DE, morphometry, histopathology, and vasoactive-inotropic score (VIS) were compared between children with (n=226) and without (n=160) cirrhosis listed for liver transplantation (LT) over 2011-2021. Discriminatory performance of left ventricular mass index (height)2.7(LVMI g/m2.7) for predicting waitlist decompensation, composite serious adverse events post liver transplant and mortality was assessed using ROC analysis, with AUCs and optimal thresholds compared against PELD-Cr/MELD scores. RESULTS: LV mass was significantly higher in children with cirrhosis on 2DE and necropsy specimens compared to non-cirrhotic controls, with ∼25% demonstrating LV hypertrophy, with OR of 6.9 [CI 3,16], p< 0.0001. In the cirrhotic cohort, LVMI correlated with vasoactive needs under stress of LT (p <0.001) and was significantly higher in patients with WLD, CSAE, and non-survivors. In cirrhosis, LVMI values ≥ 88 g/m2.7, ≥ 91 g/m2.7, and ≥ 95 g/m2.7 were independently associated with WLD, CSAE, and mortality, when adjusting for PELD-Cr/MELD, bilirubin, and INR (p <0.01). Combining LVMI + PELD-Cr/MELD significantly outperformed PELD-Cr/MELD in discriminating both WLD and CSAE, whereas LVMI alone significantly outperformed PELD-Cr/MELD for CSAE and was comparable for WLD. All three models performed comparably in discriminating death. CONCLUSION: LVMI is a strong predictor of morbidity and mortality, serving as a prognostic marker in children with cirrhosis. Incorporating LVMI into PELD-Cr/MELD may enhance risk stratification and organ allocation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Bashir DA, Thadani S, Nack T, et al. Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis. J Hepatol. 2026. PMID: 42863682. doi:10.1016/j.jhep.2026.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。